Crestor 40 mg Nórsko - nórčina - Statens legemiddelverk

crestor 40 mg

orifarm as - rosuvastatinkalsium - tablett, filmdrasjert - 40 mg

Crestor 20 mg Nórsko - nórčina - Statens legemiddelverk

crestor 20 mg

orifarm as - rosuvastatinkalsium - tablett, filmdrasjert - 20 mg

Zenon 40 mg / 10 mg Nórsko - nórčina - Statens legemiddelverk

zenon 40 mg / 10 mg

paranova as - rosuvastatinkalsium / ezetimib - tablett, filmdrasjert - 40 mg / 10 mg

Zenon 10 mg / 10 mg Nórsko - nórčina - Statens legemiddelverk

zenon 10 mg / 10 mg

orifarm as - rosuvastatinkalsium / ezetimib - tablett, filmdrasjert - 10 mg / 10 mg

Zenon 20 mg / 10 mg Nórsko - nórčina - Statens legemiddelverk

zenon 20 mg / 10 mg

orifarm as - rosuvastatinkalsium / ezetimib - tablett, filmdrasjert - 20 mg / 10 mg

Zenon 40 mg / 10 mg Nórsko - nórčina - Statens legemiddelverk

zenon 40 mg / 10 mg

orifarm as - rosuvastatinkalsium / ezetimib - tablett, filmdrasjert - 40 mg / 10 mg

Dronedaron Aristo 400 mg Nórsko - nórčina - Statens legemiddelverk

dronedaron aristo 400 mg

aristo pharma gmbh - dronedaronhydroklorid - tablett, filmdrasjert - 400 mg

Kaletra Európska únia - nórčina - EMA (European Medicines Agency)

kaletra

abbvie deutschland gmbh co. kg - lopinavir, ritonavir - hiv-infeksjoner - antivirals for systemic use, protease inhibitors - kaletra er angitt i kombinasjon med andre antiretrovirale legemidler til behandling av hiv-1-infiserte voksne, ungdommer og barn i alderen 14 og eldre. valg av kaletra til å behandle protease inhibitor opplevd hiv-1 infiserte pasienter bør være basert på individuelle viral motstand testing og behandling historie av pasienter.

Orserdu Európska únia - nórčina - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - bryst neoplasms - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Tabrecta Európska únia - nórčina - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karsinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.